base metals investing Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
base metals investing Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
base metals investing Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
base metals investing Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
base metals investing Mesoblast Acquires Chimeric Antigen Receptor Platform Technology for Precision-Enhanced Cell Products
base metals investing Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
base metals investing Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
SAGA Metals Completes Acquisition of Wolverine Heavy Rare Earth Element Project in Labrador-REE Mineralized Potential Similar to Strange Lake and Tanbreez
Golconda Gold Releases Q2 2026 Production Update at Galaxy And Announces Mobilisation of Mining Contractor at Summit
